Expression of heparan sulfate in gastric carcinoma and its correlation with clinicopathological features and patient survival

Journal of Clinical Pathology

Volumn 64, Issue 2, 2011, Pages 153-158

  Lo, Soo Ling ^a   Thike, Aye Aye ^b   Tan, Soo Yong ^b   Lim, Tony Kiat Hon ^b   Tan, Iain Bee Huat ^c   Choo, Su Pin ^c   Tan, Puay Hoon ^b   Bay, Boon Huat ^a   Yip, George Wai Cheong ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b SINGAPORE GENERAL HOSPITAL   (Singapore)

^c DIVISION OF MEDICAL ONCOLOGY   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARAN SULFATE; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; CANCER INFILTRATION; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; EPITHELIUM; FEMALE; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LYMPH NODE METASTASIS; LYMPH VESSEL; MAJOR CLINICAL STUDY; MALE; PATHOLOGY; PERINEURIUM; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; STOMACH CARCINOMA; STOMACH LESION; TISSUE MICROARRAY; TUMOR RECURRENCE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CELL DIFFERENTIATION; EPIDEMIOLOGIC METHODS; FEMALE; HEPARITIN SULFATE; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; PROGNOSIS; STOMACH NEOPLASMS; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 79151481673     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jcp.2010.087478     Document Type: Article

References (65)

1. Garcia M, Jemal A, Ward EM, et al. Global Cancer Facts & Figures 2007. Atlanta: American Cancer Society, 2007.
2. Parkin DM. International variation. Oncogene 2004;23:6329-40.
3. Seow A, Koh WP, Chia KS, et al. Trends in Cancer Incidence in Singapore 1968-2002. Singapore: Singapore Cancer Registry, 2004.
4. Marugame T, Dongmei Q. Comparison of time trends in stomach cancer incidence (1973-1997) in East Asia, Europe and USA, from Cancer Incidence in Five Continents Vol. IV-VIII. Jpn J Clin Oncol 2007;37:242-3.
5. Yip GW, Smollich M, Gotte M. Therapeutic value of glycosaminoglycans in cancer. Mol Cancer Ther 2006;5:2139-48.
6. Varki A, Cummings RD, Esko JD, et al. Essentials of Glycobiology. 2nd edn. New York: Cold Spring Harbor Laboratory Press, 2008.
7. Bernfield M, Gotte M, Park PW, et al. Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem 1999;68:729-77. (Pubitemid 29449208)
8. Koo CY, Sen YP, Bay BH, et al. Targeting heparan sulfate proteoglycans in breast cancer treatment. Recent Pat Anticancer Drug Discov 2008;3:151-8.
9. Sasisekharan R, Shriver Z, Venkataraman G, et al. Roles of heparan-sulphate glycosaminoglycans in cancer. Nat Rev Cancer 2002;2:521-8.
10. Fuster MM, Esko JD. The sweet and sour of cancer: glycans as novel therapeutic targets. Nat Rev Cancer 2005;5:526-42.
11. Lortat-Jacob H. The molecular basis and functional implications of chemokine interactions with heparan sulphate. Curr Opin Struct Biol 2009;19:543-8.
12. Perrimon N, Bernfield M. Specificities of heparan sulphate proteoglycans in developmental processes. Nature 2000;404:725-8. (Pubitemid 30212391)
13. Blackhall FH, Merry CL, Davies EJ, et al. Heparan sulfate proteoglycans and cancer. Br J Cancer 2001;85:1094-8.
14. Yip GW, Ferretti P, Copp AJ. Heparan sulphate proteoglycans and spinal neurulation in the mouse embryo. Development 2002;129:2109-19. (Pubitemid 34874225)
15. Gotte M, Spillmann D, Yip GW, et al. Changes in heparan sulfate are associated with delayed wound repair, altered cell migration, adhesion and contractility in the galactosyltransferase I (beta4GalT-7) deficient form of Ehlers-Danlos syndrome. Hum Mol Genet 2008;17:996e1009.
16. Iozzo RV, Zoeller JJ, Nystrom A. Basement membrane proteoglycans: modulators par excellence of cancer growth and angiogenesis. Mol Cells 2009;27:503-13.
17. Li JP, Vlodavsky I. Heparin, heparan sulfate and heparanase in inflammatory reactions. Thromb Haemost 2009;102:823-8.
18. Nikolova V, Koo CY, Ibrahim SA, et al. Differential roles for membrane-bound and soluble syndecan-1 (CD138) in breast cancer progression. Carcinogenesis 2009;30:397-407.
19. Koo CY, Bay BH, Lui PC, et al. Immunohistochemical expression of heparan sulfate correlates with stromal cell proliferation in breast phyllodes tumors. Mod Pathol 2006;19:1344-50.
20. Guo CH, Koo CY, Bay BH, et al. Comparison of the effects of differentially sulphated bovine kidney- and porcine intestine-derived heparan sulphate on breast carcinoma cellular behaviour. Int J Oncol 2007;31:1415-23.
21. Jayson GC, Lyon M, Paraskeva C, et al. Heparan sulfate undergoes specific structural changes during the progression from human colon adenoma to carcinoma in vitro. J Biol Chem 1998;273:51-7.
22. Jayson GC, Vives C, Paraskeva C, et al. Coordinated modulation of the fibroblast growth factor dual receptor mechanism during transformation from human colon adenoma to carcinoma. Int J Cancer 1999;82:298-304. (Pubitemid 29293792)
23. Chen Z, Fan JQ, Li J, et al. Promoter hypermethylation correlates with the Hsulf-1 silencing in human breast and gastric cancer. Int J Cancer 2009;124:739-44.
24. Kirn-Safran C, Farach-Carson MC, Carson DD. Multifunctionality of extracellular and cell surface heparan sulfate proteoglycans. Cell Mol Life Sci 2009;66:3421-34.
25. Wiksten JP, Lundin J, Nordling S, et al. Epithelial and stromal syndecan-1 expression as predictor of outcome in patients with gastric cancer. Int J Cancer 2001;95:1-6. (Pubitemid 32118604)
26. Zhu Z, Friess H, Kleeff J, et al. Glypican-3 expression is markedly decreased in human gastric cancer but not in esophageal cancer. Am J Surg 2002;184:78-83. (Pubitemid 34804883)
27. Tan PH, Jayabaskar T, Yip G, et al. p53 and c-kit (CD117) protein expression as prognostic indicators in breast phyllodes tumors: a tissue microarray study. Mod Pathol 2005;18:1527-34. (Pubitemid 41670650)
28. Teng YH, Tan PH, Chia SJ, et al. Increased expression of non-sulfated chondroitin correlates with adverse clinicopathological parameters in prostate cancer. Mod Pathol 2008;21:893-901.
29. Linhardt RJ, Turnbull JE, Wang HM, et al. Examination of the substrate specificity of heparin and heparan sulfate lyases. Biochemistry 1990;29:2611-17.
30. Nader HB, Porcionatto MA, Tersariol IL, et al. Purification and substrate specificity of heparitinase I and heparitinase II from Flavobacterium heparinum. Analyses of the heparin and heparan sulfate degradation products by 13C NMR spectroscopy. J Biol Chem 1990;265:16807-13.
31. Desai UR, Wang HM, Linhardt RJ. Specificity studies on the heparin lyases from Flavobacterium heparinum. Biochemistry 1993;32:8140-5.
32. Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;345:725-30.
33. Oshiro M, Ono K, Suzuki Y, et al. Immunohistochemical localization of heparan sulfate proteoglycan in human gastrointestinal tract. Histochem Cell Biol 2001;115:373-80. (Pubitemid 32467750)
34. Theocharis AD, Vynios DH, Papageorgakopoulou N, et al. Altered content composition and structure of glycosaminoglycans and proteoglycans in gastric carcinoma. Int J Biochem Cell Biol 2003;35:376-90. (Pubitemid 36084460)
35. David G, Bai XM, Van der Schueren B, et al. Developmental changes in heparan sulfate expression: in situ detection with mAbs. J Cell Biol 1992;119:961-75.
36. Mani K, Cheng F, Sandgren S, et al. The heparan sulfate-specific epitope 10E4 is NO-sensitive and partly inaccessible in glypican-1. Glycobiology 2004;14:599-607.
37. Hamza D, Lucas R, Feizi T, et al. First synthesis of heparan sulfate tetrasaccharides containing both N-acetylated and N-unsubstituted glucosamine-search for putative 10E4 epitopes. Chembiochem 2006;7:1856-8.
38. Inki P, Joensuu H, Grenman R, et al. Association between syndecan-1 expression and clinical outcome in squamous cell carcinoma of the head and neck. Br J Cancer 1994;70:319-23.
39. Nackaerts K, Verbeken E, Deneffe G, et al. Heparan sulfate proteoglycan expression in human lung-cancer cells. Int J Cancer 1997;74:335-45.
40. Lundin M, Nordling S, Lundin J, et al. Epithelial syndecan-1 expression is associated with stage and grade in colorectal cancer. Oncology 2005;68:306-13.
41. Barbareschi M, Maisonneuve P, Aldovini D, et al. High syndecan-1 expression in breast carcinoma is related to an aggressive phenotype and to poorer prognosis. Cancer 2003;98:474-83.
42. Davies EJ, Blackhall FH, Shanks JH, et al. Distribution and clinical significance of heparan sulfate proteoglycans in ovarian cancer. Clin Cancer Res 2004;10:5178-86.
43. Leivonen M, Lundin J, Nordling S, et al. Prognostic value of syndecan-1 expression in breast cancer. Oncology 2004;67:11-18.
44. Zellweger T, Ninck C, Bloch M, et al. Expression patterns of potential therapeutic targets in prostate cancer. Int J Cancer 2005;113:619-28.
45. Lai J, Chien J, Staub J, et al. Loss of HSulf-1 up-regulates heparin-binding growth factor signaling in cancer. J Biol Chem 2003;278:23107-17.
46. Narita K, Chien J, Mullany SA, et al. Loss of HSulf-1 expression enhances autocrine signaling mediated by amphiregulin in breast cancer. J Biol Chem 2007;282:14413-20.
47. Zhao ZS, Zhou JL, Yao GY, et al. Correlative studies on bFGF mRNA and MMP-9 mRNA expressions with microvascular density, progression, and prognosis of gastric carcinomas. World J Gastroenterol 2005;11:3227-33.
48. Nurcombe V, Smart CE, Chipperfield H, et al. The proliferative and migratory activities of breast cancer cells can be differentially regulated by heparan sulfates. J Biol Chem 2000;275:30009-18.
49. Mundhenke C, Meyer K, Drew S, et al. Heparan sulfate proteoglycans as regulators of fibroblast growth factor-2 receptor binding in breast carcinomas. Am J Pathol 2002;160:185-94. (Pubitemid 34052279)
50. Delehedde M, Deudon E, Boilly B, et al. Heparan sulfate proteoglycans play a dual role in regulating fibroblast growth factor-2 mitogenic activity in human breast cancer cells. Exp Cell Res 1996;229:398-406. (Pubitemid 27026930)
51. Fernig DG, Chen HL, Rahmoune H, et al. Differential regulation of FGF-1 and -2 mitogenic activity is related to their kinetics of binding to heparan sulfate in MDA-MB-231 human breast cancer cells. Biochem Biophys Res Commun 2000;267:770-6. (Pubitemid 30099399)
52. Gotte M, Yip GW. Heparanase, hyaluronan, and CD44 in cancers: a breast carcinoma perspective. Cancer Res 2006;66:10233-7.
53. Elkin M, Ilan N, Ishai-Michaeli R, et al. Heparanase as mediator of angiogenesis: mode of action. FASEB J 2001;15:1661-3.
54. Ilan N, Elkin M, Vlodavsky I. Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis. Int J Biochem Cell Biol 2006;38:2018-39.
55. Takaoka M, Naomoto Y, Ohkawa T, et al. Heparanase expression correlates with invasion and poor prognosis in gastric cancers. Lab Invest 2003;83:613-22.
56. Wang Z, Xu H, Jiang L, et al. Positive association of heparanase expression with tumor invasion and lymphatic metastasis in gastric carcinoma. Mod Pathol 2005;18:205-11.
57. Xie ZJ, Liu Y, Jia LM, et al. Heparanase expression, degradation of basement membrane and low degree of infiltration by immunocytes correlate with invasion and progression of human gastric cancer. World J Gastroenterol 2008;14:3812-18.
58. Zheng LD, Jiang GS, Pu JR, et al. Stable knockdown of heparanase expression in gastric cancer cells in vitro. World J Gastroenterol 2009;15:5442-8.
59. Zheng L, Jiang G, Mei H, et al. Small RNA interference-mediated gene silencing of heparanase abolishes the invasion, metastasis and angiogenesis of gastric cancer cells. BMC Cancer 2010;10:33.
60. Mrena J, Wiksten JP, Nordling S, et al. MMP-2 but not MMP-9 associated with COX-2 and survival in gastric cancer. J Clin Pathol 2006;59:618-23. (Pubitemid 43886046)
61. Zheng H, Takahashi H, Murai Y, et al. Expressions of MMP-2, MMP-9 and VEGF are closely linked to growth, invasion, metastasis and angiogenesis of gastric carcinoma. Anticancer Res 2006;26:3579-83.
62. Alakus H, Grass G, Hennecken JK, et al. Clinicopathological significance of MMP-2 and its specific inhibitor TIMP-2 in gastric cancer. Histol Histopathol 2008;23:917-23.
63. Chambers AF, Matrisian LM. Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 1997;89:1260-70.
64. John A, Tuszynski G. The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis. Pathol Oncol Res 2001;7:14-23. (Pubitemid 32591662)
65. Munesue S, Yoshitomi Y, Kusano Y, et al. A novel function of syndecan-2, suppression of matrix metalloproteinase-2 activation, which causes suppression of metastasis. J Biol Chem 2007;282:28164-74.